Classical Hodgkin Lymphoma · line 1 · None
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | None |
| ID | IND-CHL-PREGNANCY-MOD-ABVD |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-CHL |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Special-population indication for CHL in 2nd-3rd trimester pregnancy. Multidisciplinary care mandatory. Registry data underpin safety profile; randomized data not feasible.
Used By
No reverse references found in the YAML corpus.